ReviewFrontiers in nutrition2025
Targeting the blood-brain barrier with phytochemicals to attenuate vascular cognitive impairment: mechanisms and therapeutic potential across etiologies.
Review in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dietary (Poly)phenol Intake, Inflammatory Biomarkers, and Mild Cognitive Impairment in Italian Adults.Antioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular cognitive impairment (VCI), a cognitive disorder arising from cerebrovascular pathology, currently lacks effective targeted therapies. Dysfunction of the blood-brain barrier (BBB) represents a pivotal event in VCI pathogenesis, characterized by tight junction degradation, neuroinflammation, and oxidative stress. Phytochemicals-including polyphenols, flavonoids, and polysaccharides-demonstrate promising multi-target potential in ameliorating VCI by preserving BBB integrity, mitigating neuroinflammation and oxidative stress, exerting neuroprotective effects, and modulating the gut-brain axis. However, the clinical translation of these compounds is currently impeded by low bioavailability and limited BBB permeability. Prioritizing the development of targeted delivery systems is essential to enhance the therapeutic efficacy and clinical utility of phytochemicals in the prevention and treatment of VCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.